Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients

被引:89
作者
Bervoets, ARJ
Spasovski, GB
Behets, GJ
Dams, G
Polenakovic, MH
Zafirovska, K
Van Hoof, VO
De Broe, ME
D'Haese, PC
机构
[1] Univ Antwerp, Dept Nephrol Hypertens, Antwerp, Belgium
[2] Univ Skopje, Dept Nephrol, Skopje, North Macedonia
关键词
adynamic bone disease (ABD); renal osteodystrophy (ROD); biochemical markers; osteocalcin (OC); bone alkaline phosphatase (BAP); end-stage renal failure (ESRF);
D O I
10.1016/S0272-6386(03)00197-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Various biochemical markers have been evaluated in dialysis patients for the diagnosis of renal osteodystrophy (ROD). However, their value in predialysis patients with end-stage renal failure (ESRF) is not yet clear. Methods: Bone histomorphometric evaluation was performed and biochemical markers of bone turnover were determined in serum of an unselected predialysis ESRF population (N = 84). Results Significant (P < 0.005) differences between the five groups with ROD (ie, normal bone [N = 32], adynamic bone [ABD; N = 19], hyperparathyroidism [N = 8], osteomalacia [OM; N = 10], and mixed lesion [N = 15]) were noted for intact parathyroid hormone, total (TAP) and bone alkaline phosphatase (BAP), osteocalcin (OC), and serum calcium levels. Serum creatinine and (deoxy)pyridinoline levels did not differ between groups. For the diagnosis of ABD, an OC level of 41 mu g/L or less (<= 7.0 nmol/L) had a sensitivity of 83% and specificity of 67%. The positive predictive value (PPV) for the population under study was 47%. The combination of an OC level of 41 ng/L or less (<= 7.0 nmol/L) with a BAP level of 23 U/L or less increased the sensitivity, specificity, and PPV to 72%, 89%, and 77%, respectively. ABD and normal bone taken as one group could be detected best by a BAP level of 25 U/L or less and TAP level of 84 U/L or less, showing sensitivities of 72% and 88% and specificities of 76% and 60%, corresponding with PPVs of 89% and 85%, respectively. In the absence of aluminum or strontium exposure, serum calcium level was found to be a useful index for the diagnosis of OM. Conclusion: OC, TAP, BAP, and serum calcium levels are useful in the diagnosis of ABD, normal bone, and OM in predialysis patients with ESRF.
引用
收藏
页码:997 / 1007
页数:11
相关论文
共 66 条
[1]  
ANDRESS DL, 1986, J BONE MINER RES, V1, P391
[2]   OSTEOMALACIA AND APLASTIC BONE-DISEASE IN ALUMINUM-RELATED OSTEODYSTROPHY [J].
ANDRESS, DL ;
MALONEY, NA ;
COBURN, JW ;
ENDRES, DB ;
SHERRARD, DJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 65 (01) :11-16
[3]   Risk factors for vertebral fractures in renal osteodystrophy [J].
Atsumi, K ;
Kushida, K ;
Yamazaki, K ;
Shimizu, S ;
Ohmura, A ;
Inoue, T .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (02) :287-293
[4]   HIGH BONE TURNOVER ASSOCIATED WITH AN ALUMINUM-INDUCED IMPAIRMENT OF BONE MINERALIZATION [J].
CHARHON, SA ;
CHAVASSIEUX, PM ;
CHAPUY, MC ;
TRAEGER, J ;
MEUNIER, PJ .
BONE, 1986, 7 (05) :319-324
[5]   SERUM BONE GLA-PROTEIN IN RENAL OSTEODYSTROPHY - COMPARISON WITH BONE HISTOMORPHOMETRY [J].
CHARHON, SA ;
DELMAS, PD ;
MALAVAL, L ;
CHAVASSIEUX, PM ;
ARLOT, M ;
CHAPUY, MC ;
MEUNIER, PJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (04) :892-897
[6]   Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study [J].
Coen, G ;
Mazzaferro, S ;
Ballanti, P ;
Sardella, D ;
Chicca, S ;
Manni, M ;
Bonucci, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (05) :813-819
[7]   Renal osteodystrophy in predialysis and hemodialysis patients: Comparison of histologic patterns and diagnostic predictivity of intact PTH [J].
Coen, G ;
Ballanti, P ;
Bonucci, E ;
Calabria, S ;
Costantini, S ;
Ferrannini, M ;
Giustini, M ;
Giordano, R ;
Nicolai, G ;
Manni, M ;
Sardella, D ;
Taggi, F .
NEPHRON, 2002, 91 (01) :103-111
[8]   NON-ALUMINIC ADYNAMIC BONE-DISEASE IN NON-DIALYZED UREMIC PATIENTS - A NEW TYPE OF OSTEOPATHY DUE TO OVERTREATMENT [J].
COHENSOLAL, ME ;
SEBERT, JL ;
BOUDAILLIEZ, B ;
WESTEEL, PF ;
MORINIERE, PH ;
MARIE, A ;
GARABEDIAN, M ;
FOURNIER, A .
BONE, 1992, 13 (01) :1-5
[9]  
Couttenye MM, 1996, NEPHROL DIAL TRANSPL, V11, P1065
[10]   Increased bone strontium levels in hemodialysis patients with osteomalacia [J].
D'Haese, PC ;
Schrooten, I ;
Goodman, WG ;
Cabrera, WE ;
Lamberts, LV ;
Elseviers, MM ;
Couttenye, MM ;
De Broe, ME .
KIDNEY INTERNATIONAL, 2000, 57 (03) :1107-1114